Explore /
Poster
/ Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T).

Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T).

Authors

Jennifer S. LoCoco

Illumina, Inc., San Diego, CA

Jennifer S. LoCoco , Biswajit Das , Sorena Rahmanian , Ting-Chia Chang , Jennifer Silhavy , Li Chen , Robin Harrington , Amanda Peach , Yao Fu , Lisa McShane , Jessica Li , Alice P. Chen , Naoko Takebe , Lyndsay Harris , David R. Patton , Traci L. Pawlowski , Phillip G. Febbo , James H. Doroshow , P. Mickey Williams , Chris Alan Karlovich

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Circulating Biomarkers

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3047)

DOI

10.1200/JCO.2023.41.16_suppl.3047

Abstract #

3047

Poster Bd #

245

Abstract Disclosures

Similar Posters

Poster

2017 ASCO Annual Meeting

Hedgehog inhibition impaired platinum response in high-grade serous ovarian cancer harboring high hedgehog ligand expression and mTOR pathway activation.

First Author: Gwo Yaw Ho

Poster

2016 ASCO Annual Meeting

$MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway.$